Lutetium-177 PSMA-617 radioligand therapy
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-LUTETIUM-177-PSMA |
|---|
| ID | REG-LUTETIUM-PSMA |
|---|---|
| Type | Regimen |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Notes
VISION trial: significant rPFS + OS benefit in PSMA-PET-positive mCRPC post-ARPI + post-taxane. Requires nuclear medicine infrastructure + PSMA-PET. UA access concentrated in 2-3 academic centers.
Used By
Contraindications
CI-PROSTATE-LUTETIUM-VISCERAL-ONLY- CI-PROSTATE-LUTETIUM-VISCERAL-ONLY
Indication
IND-PROSTATE-MCRPC-2L-LU-PSMA- IND-PROSTATE-MCRPC-2L-LU-PSMA